Regulation of S100beta in Melanoma by HOXC11 and SRC-1
Author Information
Author(s): deBlacam C, Byrne C, Hughes E, McIlroy M, Bane F, Hill A D K, Young L S
Primary Institution: Royal College of Surgeons in Ireland
Hypothesis
The study investigates the regulation of S100beta in cutaneous melanoma by HOXC11 and SRC-1 and the potential modulation by dasatinib.
Conclusion
The study defines a signaling mechanism regulating S100beta in melanoma, which can be modulated by dasatinib.
Supporting Evidence
- HOXC11 and SRC-1 were significantly elevated in malignant melanoma compared to benign nevi.
- Dasatinib reduced S100beta expression and migration in melanoma cell lines.
- HOXC11 recruitment to the S100beta promoter was confirmed in primary melanoma cells.
Takeaway
This study looks at how certain proteins help control a marker for melanoma, and a drug called dasatinib can change this process.
Methodology
The study used immunohistochemistry, immunofluorescence, western blot, qPCR, ChIP, and migration assays to investigate the regulation of S100beta.
Participant Demographics
Patients with malignant melanoma and benign nevi.
Statistical Information
P-Value
P<0.001 and P=0.017
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website